EPRX
Eupraxia Pharmaceuticals Inc.NASDAQHealthcare$7.17-2.18%ClosedMarket Cap: $240.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.51
P/S
0.00
EV/EBITDA
-4.33
DCF Value
$1.45
FCF Yield
-11.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.8%
ROA
-47.9%
ROIC
-51.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-16.4M | $-17.0M | $-0.34 | — |
| FY 2025 | $0.00 | -Infinity% | $-39.1M | $-39.2M | $-1.05 | — |
| Q3 2025 | $0.00 | -Infinity% | $-9.6M | $-8.9M | $-0.26 | — |
| Q2 2025 | $0.00 | NaN% | $-11.3M | $-11.9M | $-0.33 | — |
| Q1 2025 | $0.00 | NaN% | $-10.1M | $-9.6M | $-0.30 | — |
| Q4 2024 | $0.00 | NaN% | $-10.8M | $-10.8M | $-0.21 | — |
| FY 2024 | $0.00 | NaN% | $-38.8M | $-36.7M | $-0.76 | — |
| Q3 2024 | $0.00 | NaN% | $-8.5M | $-8.1M | $-0.17 | — |
| Q2 2024 | $0.00 | NaN% | $-9.0M | $-8.2M | $-0.17 | — |
| Q1 2024 | $0.00 | NaN% | $-6.7M | $-6.0M | $-0.21 | — |
| Q4 2023 | $0.00 | NaN% | $-12.2M | $-10.2M | $-0.15 | — |
| FY 2023 | $0.00 | NaN% | $-27.8M | $-28.2M | $-1.17 | — |